Delivering therapeutic payload to specific target cells, thus increasing the efficiency and reducing adverse effects, is considered by many to be the holy grail of medical research. We designed a self-assembled modular platform named ASSET, Anchored Secondary scFv Enabling Targeting, to facilitate the construction of a theoretically unlimited repertoire of targeted carriers. By utilizing a biological approach for conjugation of monoclonal antibodies(mAbs), we were able to overcome the limitations of current methodologies. ASSET is based on a lipoprotein, self-assembles into the membrane of the LNPs and interacts with the mAbs’ Fc domain. With a simple switch of different mAbs, it redirects specific uptake of RNAs by diverse subsets.
- Veiga N, et al(2019) Leukocyte-Specific siRNA Delivery Revealing IRF8 as a Potential Anti-Inflammatory Target. J Control Release. 313:33-41.
- Veiga N, et al (2018) Cell-specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat Commun. 9(1):4493-449.
- Kedmi R, et al (2018) A modular platform for targeted RNAi therapeutics. Nature Nanotechnology.